Full Text View
Tabular View
No Study Results Posted
Related Studies
Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer
This study has been completed.
Study NCT00066768   Information provided by National Cancer Institute (NCI)

First Received on August 6, 2003.   Last Updated on December 12, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Stage IV Non-small Cell Lung Cancer
Additional conditions recognized in this trial
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
More general conditions related to this trial
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Interventions listed in this trial
suramin
docetaxel
gemcitabine hydrochloride
laboratory biomarker analysis
pharmacological study
Additional drug interventions recognized in this trial
Gemcitabine
More general drug interventions related to this trial
Anthelmintics
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antinematodal Agents
Antineoplastic Agents
Antiparasitic Agents
Antiprotozoal Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Trypanocidal Agents
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services